ASCO GU24
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
ASCO GU24
Feb 3, 2024, 17:09 |
Societies
Chandler Park: Best parts of ASCO GU 2024
Chandler Park, Kentucky Physician Representative of the ASCO State Executive Council, shared on LinkedIn: "Best…
Feb 2, 2024, 17:33 |
Drugs
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted: "Day 3 of GU24 ASCO Highlights 1. KN564: Adj Pembro w/…
Feb 1, 2024, 17:24 |
Drugs
Day 2 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter: "Day 2 of GU24 ASCO Highlights 1. UNITE: EV…
Feb 1, 2024, 17:14 |
Insight
Sumanta K. Pal: She has developed what I think should be called the 'Bergerot QOL Index ' for kidney cancer
Sumanta K. Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared…
Jan 31, 2024, 18:28 |
Drugs
Day 1 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter page: "Day 1 GU24 ASCO Highlights 1. CONTAC02: Atezo/Cabo…
Jan 30, 2024, 16:13 |
Blog
Chandler Park: Gleason 3+3=6 should NOT be considered a 'cancer'
Chandler Park, Kentucky Physician Representative of the ASCO State Executive Council, shared on X/Twitter: "Gleason…
Jan 29, 2024, 17:46 |
Insight
Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason?
Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome…
Jan 28, 2024, 18:44 |
Blog
Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas - Dana-Farber News
Dana-Farber News recently shared a post on their X/Twitter page: "ASCO GU24: Interim phase 1…
All:
8
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube